Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Provided By GlobeNewswire
Last update: Aug 19, 2025
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301
Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026
NASDAQ:CING (12/11/2025, 12:11:53 PM)
4.08
+0.13 (+3.29%)
NASDAQ:CINGW (12/11/2025, 12:08:38 PM)
0.0532
+0.02 (+43.4%)
Find more stocks in the Stock Screener
